Is Veozah (Fezolinetant) Safe While Trying to Conceive or During Pregnancy?

What Is Veozah and Who Is It Approved For?

Fezolinetant, sold under the brand name Veozah, is a selective neurokinin 3 (NK3) receptor antagonist approved by the FDA in May 2023 for moderate-to-severe vasomotor symptoms caused by menopause. It is the first non-hormonal, non-antidepressant prescription drug in this class cleared for use in the United States.

Hot flashes and night sweats happen because estrogen withdrawal dysregulates the KNDy neurons (kisspeptin/neurokinin B/dynorphin) in the hypothalamus. Neurokinin B, acting through the NK3 receptor, drives the thermoregulatory instability. Fezolinetant blocks that signal at its source.

Who the Approval Actually Covers

The SKYLIGHT 1 and SKYLIGHT 2 phase 3 trials enrolled postmenopausal women with a mean age of approximately 54 years. SKYLIGHT 2 showed a statistically significant reduction in moderate-to-severe hot flash frequency versus placebo at week 12 (mean difference roughly 2.7 events per day for the 45 mg dose). The trial populations were exclusively menopausal. No trial enrolled women who were still cycling, trying to conceive (TTC), pregnant, or breastfeeding.

That gap matters. Extrapolating menopause-trial data to reproductive-age women is scientifically unjustified, and no professional society guideline does so.

Where Fezolinetant Sits in the Drug Class

NK3 antagonists are a mechanistically distinct class from hormone therapy, SSRIs, SNRIs, and gabapentinoids. The mechanism is specific to central hypothalamic signaling, not systemic estrogen replacement. That makes it attractive for women who cannot use hormones, but it also means the reproductive safety profile has to be evaluated on its own, not borrowed from older drug classes.

Why "Trying to Conceive" Is a Distinct Safety Category

Many women assume that if a drug is "non-hormonal" it is automatically safe in pregnancy or during conception attempts. That assumption is incorrect. Non-hormonal means the drug does not add or mimic estrogen or progesterone. It says nothing about effects on fetal development, implantation, placental function, or reproductive tract physiology.

The Physiology Behind the Concern

The KNDy/NK3 system does not disappear at menopause. It plays an active role throughout reproductive life:

• Puberty onset: kisspeptin-NK3 signaling is required for the pubertal surge in GnRH.
• Menstrual cycle regulation: NK3 activation modulates the LH pulse generator; pharmacological NK3 blockade reduces LH pulse frequency in premenopausal women, as demonstrated in a 2019 study published in the Journal of Clinical Endocrinology and Metabolism.
• Pregnancy maintenance: early placental tissue expresses neurokinin receptors; the functional significance is still being characterized, but disruption is a theoretical concern.
• Fetal neurodevelopment: NK3 receptors are expressed in fetal brain tissue, raising a plausible, if unquantified, developmental risk.

Blocking this system pharmacologically during a TTC window, active conception, or pregnancy carries biological plausibility as a risk, even in the absence of definitive human outcome data.

LH Pulse Suppression and Ovulation

This is not a purely theoretical concern for women trying to conceive. The LH pulse is the signal that triggers ovulation. Research on senktide (a selective NK3 agonist) and on related antagonists confirms that pharmacological manipulation of the NK3 receptor acutely changes LH pulsatility in premenopausal women. If fezolinetant suppresses LH pulsatility in a reproductive-age woman, it could interfere with ovulation directly.

No published clinical trial has assessed ovulatory function as an endpoint in premenopausal women taking fezolinetant. That absence of data is itself a safety signal. You cannot conclude a drug is safe for TTC simply because no harm study has been done.

What the FDA Label Actually Says About Pregnancy and Fertility

The FDA prescribing information for Veozah addresses pregnancy and lactation directly, and the language is explicit.

Animal Reproductive Toxicity Data

Animal studies revealed embryo-fetal developmental toxicity at systemic exposures that were at or near those achieved with the 45 mg human therapeutic dose. Specifically, the label reports adverse fetal findings in rat and rabbit studies, including reduced fetal weights and skeletal variations at maternally toxic doses. These findings do not confirm that fezolinetant will cause the same effects in humans, but they establish that the drug crosses placental barriers in animal models and exerts biological activity in the developing organism.

The FDA label states clearly that fezolinetant should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Given that the indication is vasomotor symptom relief (not a life-threatening condition), there is essentially no clinical scenario where that benefit-risk calculus favors continuing the drug in a pregnant woman.

Pregnancy Outcome Reporting

Because no human pregnancy outcome data exist, the FDA label directs clinicians and patients to report pregnancies during fezolinetant use to the manufacturer's pregnancy registry. This is standard for drugs with insufficient human data, not a reassurance that the drug is safe.

Fertility Studies in Animals

The Veozah label notes that animal fertility studies were conducted. Reduced conception rates were observed at higher doses in rodent models, consistent with the drug's known pharmacodynamic effect on the GnRH/LH axis. These findings directly support the concern about fezolinetant's use during a TTC window.

Below is a practical framework for categorizing fezolinetant risk across reproductive life stages, synthesized from the FDA label, the NK3 receptor biology literature, and the SKYLIGHT trial populations. No single source presents this consolidated view.

| Life Stage | Evidence Base | Practical Recommendation | |---|---|---| | Postmenopause (no fertility intent) | Phase 3 RCT data (SKYLIGHT 1, 2) | Approved use; follow label guidance | | Perimenopause, still cycling, no TTC | No RCT data; NK3/LH biology raises ovulatory concern | Discuss risk-benefit; generally avoid | | Actively trying to conceive | Animal fertility data show reduced conception; LH pulse data suggest ovulatory interference | Discontinue before TTC | | Confirmed pregnancy | Animal embryo-fetal toxicity; no human data; non-life-threatening indication | Discontinue immediately | | Breastfeeding | No human milk data; no animal lactation transfer data | Avoid; no safety basis exists |

Pregnancy and Lactation Safety: The Required Clinical Assessment

Is Fezolinetant Safe in Pregnancy?

No. Based on current evidence, fezolinetant should not be used during pregnancy. The clinical reasoning:

1. Animal embryo-fetal toxicity was observed at exposures comparable to the human therapeutic dose, according to the Veozah FDA label.
2. No human pregnancy outcome data exist.
3. The drug's indication (vasomotor symptom relief) does not represent a life-threatening condition where risk might be accepted.
4. NK3 receptor activity in placental and fetal tissue is biologically plausible as a route of harm.

If you find out you are pregnant while taking Veozah, stop the medication and contact your obstetric provider the same day. Do not attempt to taper or self-adjust.

Breastfeeding and Lactation Transfer

No data are available on fezolinetant transfer into human breast milk, its effects on milk production, or its effects on a breastfeeding infant. The NIH LactMed database does not currently contain a substantive entry supporting fezolinetant use during lactation, and the FDA label advises against breastfeeding while taking the drug.

The NK3 receptor system influences prolactin regulation and oxytocin pathways in some animal models. Whether fezolinetant disrupts milk production in lactating women is unknown, but the pharmacological plausibility and the absence of safety data are both sufficient reasons to avoid it.

Standard clinical guidance: if you need vasomotor symptom treatment while breastfeeding, discuss non-pharmacological options (CBT-based thermal strategies, clinical hypnosis) or drugs with actual lactation safety data (certain low-dose SSRIs, though none are free of risk) with your physician.

Contraception Requirements

Fezolinetant is not classified as a known teratogen requiring a formal REMS-linked contraception program (like isotretinoin or thalidomide). But the animal embryo-fetal toxicity data mean that reliable contraception is clinically advisable for any woman of reproductive age who is taking fezolinetant and is not currently trying to conceive.

The drug does not have contraceptive properties. If you are perimenopausal and still have any possibility of ovulation, you need a separate contraceptive method. The Menopause Society notes that perimenopause does not equal infertility, and pregnancies in the late 40s, while uncommon, do occur.

Evidence Gaps: What We Do Not Know and Why That Matters

Women have been historically underrepresented in pharmaceutical trials, and the fezolinetant data set is no exception. Every phase 3 trial enrolled postmenopausal women. This means the following are entirely extrapolated or simply unknown:

• Whether fezolinetant affects ovarian reserve
• Whether it impairs luteal phase function
• Whether LH pulse suppression seen with related NK3 agents translates to clinically meaningful anovulation in humans
• Whether exposure in early pregnancy (before a woman knows she is pregnant) carries quantifiable miscarriage or malformation risk
• Whether it transfers into breast milk at concentrations detectable by a nursing infant
• What the dose-response relationship looks like for any reproductive outcome

A 2021 systematic review in Fertility and Sterility on neurokinin B signaling in reproductive biology highlights how central this pathway is to ovarian function, underscoring why the absence of preconception safety data for an NK3 antagonist is a genuine gap, not a minor oversight.

Being honest about these gaps is not a reason to panic. It is a reason to make an informed decision with your clinician rather than assuming safety based on the drug's non-hormonal label.

Who Veozah Is Right For (and Who Should Not Take It)

Appropriate Candidates

Veozah is designed for postmenopausal women with moderate-to-severe hot flashes who:

• Cannot or choose not to use hormone therapy (e.g., estrogen-sensitive cancers, personal preference)
• Have not responded to or tolerated SSRIs, SNRIs, or gabapentinoids
• Want a non-hormonal, non-CNS mechanism

The SKYLIGHT 4 open-label safety extension followed patients for 52 weeks and found a liver enzyme elevation signal requiring monitoring, so fezolinetant also carries a contraindication in women with moderate-to-severe hepatic impairment.

Women Who Should Not Take Veozah

• Pregnant women (animal embryo-fetal toxicity; no human safety data)
• Women actively trying to conceive (animal fertility effects; LH pulse biology; no human TTC safety data)
• Breastfeeding women (no lactation transfer data)
• Women with moderate-to-severe liver disease (per FDA label)
• Women taking strong CYP1A2 inhibitors such as fluvoxamine or ciprofloxacin, which can substantially increase fezolinetant plasma concentrations

Perimenopausal Women: A Gray Zone

Perimenopause is the most complicated life stage for fezolinetant. Perimenopausal women:

• Still have irregular ovulatory cycles
• May be trying to conceive (spontaneous perimenopause pregnancy is possible, though less likely)
• Experience hot flashes and night sweats that can be severe
• Were not enrolled in the SKYLIGHT trials

If you are perimenopausal and considering Veozah, your clinician needs to confirm you are not trying to conceive, that you are using reliable contraception, and that you understand the absence of trial data in your specific hormonal stage. This is a shared decision, not a simple prescription.

What to Use Instead If You Need VMS Relief While TTC or Pregnant

No pharmacological option for hot flashes has a clean safety record across the TTC-through-pregnancy continuum. The safest approach is to minimize pharmacological exposure during this window and use the strategies with the strongest non-pharmacological evidence base.

Non-Pharmacological Options With Evidence

• Cognitive Behavioral Therapy (CBT) for hot flashes: A 2021 Cochrane review found CBT reduced hot flash problem rating scores significantly versus control, with no fetal or reproductive safety concerns.
• Clinical hypnosis: A randomized trial published in Menopause (2013) showed a 74% reduction in hot flash scores with structured hypnosis sessions.
• Temperature management: cooling the sleeping environment to below 65 degrees Fahrenheit, layered bedding, cooling wristbands. Low evidence, zero fetal risk.

Pharmacological Alternatives: Use With Extreme Caution

If symptoms are severe enough to require medication, the discussion with your OB or MFM specialist needs to include:

• SSRIs/SNRIs: paroxetine (the only FDA-approved non-hormonal VMS drug prior to fezolinetant, brand name Brisdelle) carries Category D data in late pregnancy (neonatal adaptation syndrome) and should generally be avoided. Escitalopram and venlafaxine have been used but carry their own pregnancy-safety discussions.
• Gabapentin: Limited data; not indicated in pregnancy for VMS.
• Clonidine: Crosses the placenta; limited VMS efficacy data; not a clear win.

The honest answer is that there is no pharmacological VMS treatment with strong human pregnancy safety data. The least-risk path during active TTC or confirmed pregnancy is non-pharmacological management combined with close clinical follow-up.

Perimenopause, VMS, and Fertility: What Clinicians Often Forget to Say

Hot flashes during perimenopause are common. Approximately 80% of women experience vasomotor symptoms at some point during the menopausal transition, and for a meaningful subset, they begin years before the final menstrual period.

A perimenopausal woman in her mid-to-late 40s seeking a non-hormonal VMS treatment may not immediately identify as someone for whom TTC guidance applies. But clinicians prescribing fezolinetant to perimenopausal women should routinely ask about pregnancy intent. ACOG Practice Bulletin No. 141 notes that contraceptive counseling remains relevant through perimenopause until 12 consecutive months of amenorrhea confirm postmenopausal status.

As one WomanRx clinician reviewer summarized during the editorial review of this article: "The women most likely to be prescribed Veozah off-label are perimenopausal, and those are exactly the women who still need to be counseled about contraception and pregnancy risk before starting it. The non-hormonal label creates a false sense of reproductive safety."

This gap between the approved indication (postmenopause) and real-world prescribing patterns (perimenopausal women with hot flashes) is where the most important clinical conversations need to happen.

How to Talk to Your Doctor About This

If you are currently taking Veozah and planning a pregnancy, or if you were prescribed Veozah during perimenopause without a contraception discussion, bring these specific questions to your next appointment:

1. "Given that I'm still having cycles, do I need contraception while on fezolinetant?"
2. "How far in advance of TTC should I stop fezolinetant, and is there a washout period?"
3. "What do you recommend for my hot flashes while I'm trying to conceive?"
4. "If I get pregnant accidentally while on Veozah, what should I do and who should I call?"

The elimination half-life of fezolinetant is approximately 10 hours, meaning the drug clears the body relatively quickly (within approximately 2 to 3 days) after stopping. There is no evidence-based mandated washout period before TTC, but given the LH pulse effects seen with NK3 blockade, many clinicians suggest allowing at least one full menstrual cycle after stopping before attempting conception. This is extrapolated clinical reasoning, not a trial-based recommendation. Discuss it with your reproductive endocrinologist or OB.